×
About 17,198 results

ALLMedicine™ Metastatic Breast Cancer Center

Research & Reviews  4,658 results

Treatment guideline concordance, initiation, and abandonment in patients with non-metas...
https://doi.org/10.1016/S1470-2045(22)00198-X
The Lancet. Oncology; Foerster M, McCormack V et. al.

May 14th, 2022 - Comprehensive breast cancer management is essential to achieve high breast cancer survival; however, detailed reports of the treatment regimens received by patients are scarce in sub-Saharan Africa where survival is low. We aimed to examine treatm...

Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain ...
https://doi.org/10.1001/jamaoncol.2022.0514
JAMA Oncology; Tripathy D, Tolaney SM et. al.

May 14th, 2022 - Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the BEACON study did not meet its primary end poin...

Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Anal...
https://doi.org/10.1093/oncolo/oyac075
The Oncologist; Martin JM, Handorf EA et. al.

May 14th, 2022 - Metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (Her2-) breast cancer remains a significant cause of cancer-related mortality. First-line treatment with endocrine therapy (ET) with a cyclin-dependent ki...

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04941274

May 13th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is mo...

Survey on the Necessity, Sensibility, and Timing of Psycho-Oncological Counseling and t...
https://doi.org/10.1177/10547738221092104
Clinical Nursing Research; Madundo F, Hübner J et. al.

May 11th, 2022 - After the diagnosis of cancer patients require a lot of information because the disease affects all aspects of life. Some important issues regarding optimal counseling remain to be determined. This includes the time-related relevance of various to...

see more →

Guidelines  10 results

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients w...
https://doi.org/10.1016/j.annonc.2021.09.019
Annals of Oncology : Official Journal of the European Soc... Gennari A, André F et. al.

Oct 23rd, 2021 - ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.|2021|Gennari A,André F,Barrios CH,Cortés J,de Azambuja E,|diagnosis,therapy,

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2020.0016
Journal of the National Comprehensive Cancer Network : JN... Gradishar WJ, Anderson BO et. al.

Apr 8th, 2020 - Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor ...

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clini...
https://doi.org/10.1200/JOP.2017.027672
Journal of Oncology Practice; Van Poznak C, Somerfield MR et. al.

Oct 17th, 2017 - Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.|2017|Van Poznak C,Somerfield MR,Moy B,|therapeutic use,drug therapy,secondary,drug therapy,pa...

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Soci...
https://doi.org/10.1200/JCO.2016.67.1487
Journal of Clinical Oncology : Official Journal of the Am... Rugo HS, Rumble RB et. al.

May 25th, 2016 - To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 20...

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076042
Journal of Clinical Oncology : Official Journal of the Am... Partridge AH, Rumble RB et. al.

Sep 4th, 2014 - To identify optimal chemo- and targeted therapy for women with human epidermal growth factor 2 (HER2)- negative (or unknown) advanced breast cancer. A systematic review of randomized evidence (including systematic reviews and meta-analyses) from 1...

see more →

Drugs  248 results see all →

Clinicaltrials.gov  652 results

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
https://clinicaltrials.gov/ct2/show/NCT04941274

May 13th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is mo...

Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05244434

May 11th, 2022 - PRIMARY OBJECTIVE: I. To identify predictive immune biomarkers and mechanisms of response to ribociclib or palbociclib in advanced, hormone receptor positive breast cancer patients. SECONDARY OBJECTIVES: I. Identify changes in antigen presentation...

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT04869943

May 10th, 2022 - This study is a multicenter, randomized, open-label, two treatment arm, efficacy and safety study. Subjects will be randomized to the two treatment arms in a 1:1 fashion. The primary efficacy endpoint of the study will be the median rPFS. Subjects...

AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT01597388

May 10th, 2022 - A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination with Intramuscular (IM) Fulvestrant to Patients with Estrogen Receptor Positive (...

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
https://clinicaltrials.gov/ct2/show/NCT04829604

May 10th, 2022 - A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens. The ARX788 will be administered every 3 weeks ...

see more →

News  1,309 results

HER2 Expression Is a Key Determinant of Trastuzumab Deruxtecan Activity
https://www.onclive.com/view/her2-expression-is-a-key-determinant-of-trastuzumab-deruxtecan-activity

May 6th, 2022 - HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki (Enhertu), according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial (NCT04132960) pr...

Alpelisib Plus Endocrine Therapy Yields Similar PFS Benefits in Subgroup Analysis of PIK3CA-Mutated, HR+ Breast Cancer
https://www.onclive.com/view/alpelisib-plus-endocrine-therapy-yields-similar-pfs-benefits-in-subgroup-analyses-pik3ca-mutated-hr-positive-her2-negative-breast-cancer

May 6th, 2022 - The combination of alpelisib (Piqray) plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer with PIK3CA mutations, according to data from a sub...

FDA OKs Trastuzumab Deruxtecan for Earlier Use in Breast Cancer
https://www.medscape.com/viewarticle/973519

May 5th, 2022 - The US Food and Drug Administration (FDA) has granted standard approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive breast cancer who have received one prior anti-HER2 therapy. This stand...

Clinical Edge Journal Scan Commentary: Breast Cancer May 2022
https://www.mdedge.com/hematology-oncology/article/254265/breast-cancer/clinical-edge-journal-scan-commentary-breast-cancer
Erin Roesch, MD

Apr 29th, 2022 - Erin Roesch, MD The phase 2 DESTINY-Breast01 trial showed impressive antitumor activity with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in a heavily pretreated patient population with metastatic human epidermal growth factor recept.

Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast Cancer
https://www.onclive.com/view/biomarker-testing-will-fuel-next-wave-of-treatment-innovations-in-breast-cancer

Apr 29th, 2022 - Significant progress has shifted the treatment paradigm in various spaces within breast cancer, including therapy options for patients with HER2-positive metastatic breast cancer, hormone receptor (HR)–positive, HER2-negative breast cancer, and tr...

see more →

Patient Education  2 results see all →